PROCLARA BIOSCIENCES
NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
PROCLARA BIOSCIENCES
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.proclarabio.com
Total Employee:
11+
Status:
Closed
Contact:
1(617) 714-5468
Email Addresses:
[email protected]
Total Funding:
115.72 M USD
Technology used in webpage:
Amazon Wufoo
Similar Organizations
Alira Health
Alira Health is an international advisory firm.
BrainStorm Cell Therapeutics
Brainstorm is a developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders.
Cortica
Cortica is a provider of advanced neurological therapies for children with autism and other developmental differences.
HepaRegeniX
HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
LifeMine Therapeutics
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.
Novotech
Novotech is internationally recognized as a leading regional full-service CRO.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Unnatural Products
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Mérieux Equity Partners
Mérieux Equity Partners investment in Series D - Proclara Biosciences
Shire
Shire investment in Series D - Proclara Biosciences
Mérieux Equity Partners
Mérieux Equity Partners investment in Series C - Proclara Biosciences
Shire
Shire investment in Series C - Proclara Biosciences
Mérieux Equity Partners
Mérieux Equity Partners investment in Series B - Proclara Biosciences
Shire
Shire investment in Series B - Proclara Biosciences
Mérieux Equity Partners
Mérieux Equity Partners investment in Series B - Proclara Biosciences
Shire
Shire investment in Series B - Proclara Biosciences
Official Site Inspections
http://www.proclarabio.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Proclara Biosciences"
Proclara Biosciences Company Profile 2024: Valuation, …
Proclara Biosciences is headquartered in Cambridge, MA. What is the size of Proclara Biosciences? Proclara Biosciences has 19 total employees. What industry is Proclara Biosciences in? Proclara Biosciences’s primary industry is …See details»
Proclara Biosciences Company Profile | Management and
Proclara Biosciences, headquartered in Cambridge, Massachusetts, and established in 2007, is a clinical-stage biotechnology company developing novel therapies that recognize and target …See details»
Proclara Biosciences - VentureRadar
Website: http://proclarabio.com Develops novel therapies for neurodegenerative and peripheral protein misfolding diseases, aiming to impact patients with Alzheimer's, Parkinson's, and …See details»
Proclara Biosciences, Inc. Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Proclara Biosciences, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Proclara Biosciences - Crunchbase Company Profile & Funding
View contacts for Proclara Biosciences to access new leads and connect with decision-makers. NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying …See details»
Proclara Biosciences | Insights
Jan 10, 2018 · Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Proclara Biosciences - Overview, News & Similar companies
Jul 26, 2018 · View Proclara Biosciences (www.proclarabio.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well …See details»
Proclara Biosciences, Inc. - Drug pipelines, Patents, Clinical trials ...
This will be a Phase 1, randomized, double-blind, single center, placebo-controlled, multiple ascending dose (MAD) study in a maximum of 3 cohorts of 8 healthy male and female …See details»
Proclara Biosciences – Funding, Valuation, Investors, News
Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a …See details»
proclarabio.com
Proclarabio.comSee details»
Proclara Biosciences - Craft
Proclara Biosciences has 1 employees across 2 locations and $115.7 m in total funding,. See insights on Proclara Biosciences including office locations, competitors, revenue, financials, …See details»
Proclara Biosciences Inc. - life-sciences-europe.com
Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple …See details»
A Single Approach to Protein Misfolding Diseases A
Tel. +1-617-941-7020 | Fax. +1-617-714-5469 | www.proclarabio.com Senior Management Franz Hefti President & CEO Hampus Hillerstrom EVP & CFO Richard A. Fisher, PhD CSO Michael …See details»
Proclara Biosciences Announces Initiation of NPT189 Clinical ...
Jul 26, 2018 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Proclara Biosciences, a biotechnology company developing novel therapies that utilize the general amyloid interaction motif (GAIM) …See details»
Effect of NPT088 in Alpha-synuclein Overexpressing Models
Two single dose level studies of NPT088 (2 mg/kg and 20 mg/kg) systemically administered weekly for 13 weeks to alpha-synuclein overexpressing Parkinson's disease (PD) model mice …See details»
Proclara Announces Pipeline Progress - BioSpace
Jul 17, 2017 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today …See details»
Proclara Biosciences Presents New Preclinical Data ... - BioSpace
Nov 14, 2017 · Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously …See details»
What is Proclara Biosciences? Company Culture, Mission, Values
See what employees say it's like to work at Proclara Biosciences. Salaries, reviews, and more - all posted by employees working at Proclara Biosciences.See details»
Randomized, Placebo Controlled Trial of NPT088, A Phage
Here, we present the results from an initial clinical study of NPT088 in patients with mild to moderate Alzheimer’s disease. Patients were treated with 4 dose levels of NPT088 for 6 …See details»
Proclara Biosciences | VentureRadar
Website: http://proclarabio.com. Develops novel therapies for neurodegenerative and peripheral protein misfolding diseases, aiming to impact patients with Alzheimer's, Parkinson's, and …See details»